EVerZom

Executive Summary

EVerZom is a French biotechnology company pioneering exosome-based therapeutics for tissue regeneration and organ healing. Founded in 2019 and headquartered in Lyon, the company leverages its proprietary extracellular vesicle platform to develop treatments for high unmet medical needs, with a primary focus on digestive tissue healing. EVerZom has advanced its lead program into Phase 2/3 clinical trials, positioning itself as a key player in the rapidly growing exosome therapeutic space. The company's approach capitalizes on the natural intercellular communication properties of exosomes to deliver regenerative signals directly to damaged tissues, potentially offering advantages over traditional cell therapies in terms of safety, scalability, and storage. While specific financial details and total funding remain undisclosed, EVerZom's clinical progress and the strong scientific rationale behind its platform suggest significant potential. The company operates in a competitive landscape with several exosome-focused biotechs, but its focus on digestive and organ regeneration targets a substantial market opportunity. Key risks include clinical trial outcomes, manufacturing scalability, and regulatory pathway clarity for exosome products.

Upcoming Catalysts (preview)

• Q3 2026Phase 2/3 interim data readout for lead digestive healing program55% success
• Q4 2026Strategic partnership or licensing deal for exosome platform40% success
• TBDRegulatory milestone or orphan drug designation50% success